RxDoctor Payments Data

Parth Patel, DO

Internal Medicine · Auburn, NYNPI 1689168791

Payments from drug & device makers

$516in general payments, 2019–2025

Across 22 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$161
  • GSK$84
  • Teva Pharmaceuticals USA, Inc.$47
  • Boehringer Ingelheim$43
  • Astellas Pharma US Inc$36
  • Novo Nordisk$29
  • plus $114 from 6 others

What the payments were for

  • Food & beverage$516100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$516 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$43,161
Medicare patients
135
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban263$107,420
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$48,905
XareltoRivaroxaban40$35,556
TrulicityDulaglutide20$28,207
MyrbetriqMirabegron82$27,616
CreonLipase/Protease/Amylase20$26,433
Atrovent HfaIpratropium Bromide42$26,276
RybelsusSemaglutide16$26,177
JardianceEmpagliflozin25$25,518
NuedextaDextromethorphan Hbr/Quinidine29$21,621
OzempicSemaglutide20$19,878
Spiriva RespimatTiotropium Bromide24$19,034
Breo ElliptaFluticasone/Vilanterol41$16,699
MounjaroTirzepatide11$11,723
FarxigaDapagliflozin Propanediol12$11,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta$84$77,330154 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$43$54,84589 claims
Novo NordiskRybelsus, Ozempic$29$46,05636 claims
AbbVieCreon, Combigan$19$30,64336 claims
Astellas Pharma US IncMyrbetriq$36$27,61682 claims
Avanir Pharmaceuticals, Inc.Nuedexta$17$21,62129 claims
AstraZenecaFarxiga, Symbicort$25$20,55854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Auburn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →